Verification Study News Today

It’s no secret that ASIC and ASSP designs are getting more complex. First, there’s that whole thing about Moore’s Law allowing design teams to put more transistors, gates, memory cells, transceivers, processors, and acceleration engines on a chip. And, if that weren’t enough, there’s the relatively new quest to stuff an increasing number of chiplets…

Immunovia Full Year Report 2020 News provided by Share this article LUND, Sweden, Feb. 17, 2021 /PRNewswire/ --  Immunovia has today published its Full Year Report for January - December 2020. It is available on Immunovias website. "Immunovia is approaching commercial breakthrough: A sales start is planned for the first quarter of 2021. We look forward to helping patients through early detection of pancreatic cancer.  All Immunovia employees are incredibly proud of the progress we have made ...

Immunovia publishes link to Webinar No. 3 on IMMray PanCan-d: Verification Study and Clinical Use LUND, Sweden, Dec. 14, 2020 /PRNewswire/ -- Immunovia AB (publ) ("Immunovia") today published the link to the companys third webinar in a series on IMMray PanCan-d, Immunovias test for early detection of pancreatic cancer. The webinar will cover the IMMray PanCan-d verification study results and its clinical use, including feedback from experts in pancreatic cancer and pancreatic diseases. Event De...

About Immunovia Immunovia AB is a diagnostic company that is developing and commercializing highly accurate blood tests for the early detection of cancer and autoimmune diseases based on Immunovias proprietary test platform called IMMray™. Tests are based on antibody biomarker microarray analysis using advanced machine-learning and bioinformatics to single-out a set of relevant biomarkers that indicate a certain disease. Thus, forming a unique "disease biomarker signature". The company was ...